
Fuji Pharma Co Ltd
TSE:4554

Fuji Pharma Co Ltd
Tax Provision
Fuji Pharma Co Ltd
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Fuji Pharma Co Ltd
TSE:4554
|
Tax Provision
-ÂĄ1.4B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-2%
|
|
![]() |
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Tax Provision
-ÂĄ26.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
12%
|
|
![]() |
Daiichi Sankyo Co Ltd
TSE:4568
|
Tax Provision
-ÂĄ66.9B
|
CAGR 3-Years
-124%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
![]() |
Otsuka Holdings Co Ltd
TSE:4578
|
Tax Provision
ÂĄ11.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Tax Provision
-ÂĄ155.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-21%
|
|
![]() |
Astellas Pharma Inc
TSE:4503
|
Tax Provision
ÂĄ20.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Fuji Pharma Co Ltd
Glance View
Fuji Pharma Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 1,532 full-time employees. The firm is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.

See Also
What is Fuji Pharma Co Ltd's Tax Provision?
Tax Provision
-1.4B
JPY
Based on the financial report for Dec 31, 2024, Fuji Pharma Co Ltd's Tax Provision amounts to -1.4B JPY.
What is Fuji Pharma Co Ltd's Tax Provision growth rate?
Tax Provision CAGR 10Y
-2%
Over the last year, the Tax Provision growth was 14%. The average annual Tax Provision growth rates for Fuji Pharma Co Ltd have been -18% over the past three years , -9% over the past five years , and -2% over the past ten years .